The effect of monthly 50, or 100, vitamin D supplements on vitamin D status in premenopausal Middle Eastern women living in Auckland.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, women only.

Women aged ⩾20 (n=43) participated in a cross-sectional pilot study during winter (Part-I).

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and pilot study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.

What Was Measured

Topics PubMed links to this paper include Arabs, Bone Density Conservation Agents, Cholecalciferol, Dietary Supplements, Health Status, Iran and Middle East.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (European journal of clinical nutrition), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.